

INCA, LLC

International Nutraceutical Company of America, LLC
 4445 Stonington Circle
 Suite 111
 Atlanta, GA 30338
 770-455-4289 Fon 1
 770-757-3575 Fon 2
 jrmh@bellsouth.net

Maker of Revalife™

“Delivering Scientifically Proven Natural Treatments More Effectively™”

The MISERY of Osteoarthritis



“Revive Your Active Lifestyle with Revalife™”

Full time Employees 1
Part Time Employees 2

INCA's Patents

INCA has a U.S. patent pending on Revalife's™ delivery technology and will file for other patents in the U.S., Canada, Europe, China, India, Japan, Australia & New Zealand, and much of South & Central America.

The Offering

Funds To Date \$ 200 K
Funds Sought \$ 250 K

Current CAP Structure

Founders & Advisors 99 %
Private Investors 1 %

Dr. Charles W. Hofer, MBA & Board Chair
 Dr. Hofer was VP of marketing for two prior startups, and has assisted in the launch of over 20 successful startups. He is a former marketing consultant for A.T. Kearney, and is a leading authority on high potential new venture strategy. He also earned the only Regents Professorship in Entrepreneurship in the history of the University System of GA.

Executive Summary

The **International Nutraceutical Company of America, LLC (INCA)** will develop and market natural products that have been shown, in formal scientific tests, to improve their users' health. **INCA's** first product is Revalife™, a glucosamine cream for the treatment of osteoarthritis that delivers 50X more glucosamine to the affected areas than any other product on the market. **INCA** has an exclusive license on Revalife's™ patent-pending delivery technology.

The Problem: Osteoarthritis (OA) and The Ineffectiveness of Current Treatments


Arthritis is the #1 cause of disability in the U.S. It affects more people [≥ 23 million] than cancer, diabetes, or heart disease. Osteoarthritis (OA) is the most common form of arthritis. It is an incurable, debilitating joint disease caused by the deterioration of joint cartilage. Symptoms include localized pain, inflammation, reduced mobility, and deformity, requiring sufferers to alter and manage their lifestyles to prevent further deterioration. Common treatments for the pain and inflammation of OA include over-the-counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen and prescription drugs such as Celebrex™. However, these products treat only OA's symptoms, not its underlying causes. Myriad studies have shown that long-term use of these drugs increases joint deterioration. Also, chronic use of NSAIDs is dangerous: In 2000, over 107,000 patients were hospitalized and over 16,500 died because of complications associated with NSAID use.

Glucosamine: A Potential Long-term OA Treatment

Many studies have shown that glucosamine reduces OA joint pain and inflammation. Moreover, several studies have found that glucosamine prevents further joint space narrowing in OA sufferers. Overall, these benefits are documented by numerous clinical studies involving thousands of people. However, only trace amounts (less than 1%) of orally administered doses actually reach the diseased joint(s).

The Solution: Revalife™

Revalife™ is a topical cream that delivers 50 times more glucosamine to OA joints than any other product on the market. As shown in the graph on the right, Revalife™ immediately and continuously transported over 70% of its glucosamine through the skin in several scientifically accepted skin model tests. Moreover, because all of its ingredients are “Generally Recognized As Safe” (GRAS) by the U.S. Food & Drug Administration (FDA), Revalife™ does not require FDA testing or approval, and can be on the market by the summer of 2007.



Market Size

Over 23 million Americans have OA and they spend over \$6.5 billion annually on products for treating it – numbers the Arthritis Foundation projects to grow by 10%+ annually to 30 million sufferers and \$7.5 billion for treatments by 2020. Over \$1.5 billion of this total is currently spent on various forms of glucosamine.

Projected Financials

[\$ in Thousands]	2012	2013	2014	2016	2016	2018
Sales	\$250	\$1,600	\$5,987	\$16,200	\$35,511	\$61,759
COGS + Royalties	30	272	1,018	2,754	6,037	10,499
Sales & Distribution	39	711	2,439	5,598	11,439	20,641
R&D + Legal	123	75	231	646	2,635	12,605
G&A + Misc.	90	263	647	928	1,180	1,569
Net before Taxes	(\$47)	\$278	\$1,651	\$6,273	\$14,221	\$16,456

INCA's Management Team

Dr. F. Russell Denton, JD, MBA & COO
 Dr. Denton's 20 years of experience include 2 years as COO of ZymeX Pharmaceuticals, 6 years leading a Motorola division's R&D, 5 years running service firms, and 3 years as a “pharma” patent lawyer at King & Spalding. His Ph.D. is in Chemistry. His publications include seminal theories of antibiotic cocktails and patent valuation.

Target Market(s)

INCA will sell Revalife™ to OA sufferers who already use glucosamine to treat their OA. INCA will reach these individuals by selling Revalife™ to the over 3,000 U.S. arthritis and sports medicine clinics and through QVC and the Home Shopping Network.

Dr. Solomon T. Garner, Jr., VP Development
 Dr. Garner is the creator of Revalife™, and the chief inventor of the patents licensed from UGARF. His Ph.D. from the University of Georgia is in Pharmaceutical and Biomedical Sciences. He is an expert in transdermal delivery of drugs and nutraceuticals. He developed Revalife™ at the urging of his Ph.D. advisor, who has osteoarthritis.


INCA'S KEYS TO SUCCESS

1. REVALIFE™ IS A SUPERIOR PATENT-PENDING PRODUCT

Benefits	Pain Relief	Effective Delivery	Safe Delivery	Mild OA Joint Recovery	Severe OA Joint Recovery
Products					
NSAIDS e.g. Ibuprofen	YES	YES	No	No	No
COX-2 Inhibitors	YES	YES	No	No	No
Other Glucosamine Products	After 4 Weeks	No	YES	YES for Some	No
Revalife™	YES	After 4 Weeks	YES	YES	YES


2. THAT ADDRESSES AMERICA'S # 1 DISABILITY: OSTEO-ARTHRITIS

Osteoarthritis Affects over 20 Million Americans Today



Source: Centers for Disease Control and Prevention, www.cdc.gov/nccdphp/arthritis/index.htm

3. DELIVERS 50X MORE GLUCOSAMINE TO A JOINT THAN ANY OTHER PRODUCT



Source: Experiment, UGA Research Foundation, March 2004

4. AND IS PRAISED AND RECOMMENDED BY ALL WHO USE IT

"I am writing to endorse the effectiveness of Revalife™. I have certainly had more than my share of joint problems. Other than surgery, I always assumed that rest and recuperation were all that I could do to heal my injuries. Boy was I wrong. I have tried Revalife™ after joint injuries and for long-term therapy to help my recovery from nagging injuries that just do not seem to go away. As an over fifty, recovery seems to be getting more difficult as the years add up. Revalife™ works for me. I recommend it highly." Joseph E. Mason, Major U.S. Army, Retired